Celltrion Healthcare Aims For IPO After FDA Green Lights Remsima

With Celltrion still awaiting the U.S. FDA's approval of its proposed biosimilar of Remicade (infliximab), its marketing subsidiary Celltrion Healthcare is aiming to launch a planned initial public offering after the agency gives the green light to the product, in order to benefit from improved market sentiment.